The objective of this study was to elucidate the potential mechanisms by which luteolin exerts its anti-DLBCL effects through the JAK2/STAT3 signaling pathway, utilizing a combination of in vitro and in vivo assays, as well as computational studies. Here, JAK2 is linked to diffuse large B-cell lymphoma.